VRAX (Virax Biolabs Group) Beta: 1.5153 (As of Jul. 07, 2026)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group Beta?

Virax Biolabs Group VRAX -0.64% 37 Beta is 1.5153 as of Jul. 07, 2026. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), Virax Biolabs Group's Beta is 1.5153.


Virax Biolabs Group  (NAS:VRAX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Virax Biolabs Group Beta Related Terms


Virax Biolabs Group Beta Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Beta Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.68

VRAX vs BBLG, PKTX, OGEN: Beta Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Beta distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Beta falls into.


VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.5153 mean?
Virax Biolabs Group (VRAX) has a Beta of 1.5153 as of Jul. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Beta too high?
Virax Biolabs Group's current Beta is 1.5153. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Beta compare to BBLG and PKTX?
Virax Biolabs Group's Beta of 1.5153 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Virax Biolabs Group and its competitors. Virax Biolabs Group's current Beta is 1.5153. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Beta is 1.5153. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Beta is 1.5153 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • Beta: 1.5153
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value